Vanderbilt-Ingram Cancer Center

Running trials

• Recruiting

  A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

  NCT07768189· Phase 3· Corbus Pharmaceuticals Inc.· Source

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Takeda· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

  NCT07621718· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

  NCT07188896· Phase 2· Brian Rini· Source

• Recruiting

  A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06769698· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

  NCT07175441· Phase 2· Riboscience, LLC.· Source

• Recruiting

  A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

  NCT07217171· Phase 1· EvolveImmune United, Inc· Source

• Recruiting

  Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

  NCT06745908· Phase 3· ImmunityBio, Inc.· Source

• Recruiting

  Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

  NCT06966024· Phase 1· Deciphera Pharmaceuticals, LLC· Source

• Recruiting

  Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

  NCT07555210· Jessica Mezzanotte Sharpe· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  NCT06966700· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies

  NCT06486428· Addario Lung Cancer Medical Institute· Source

• Recruiting

  Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

  NCT06937177· Phase 2· Endevica Bio· Source

• Recruiting

  A Study of PHST001 in Advanced Solid Tumors

  NCT06840886· Phase 1· Pheast Therapeutics· Source

• Recruiting

  DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

  NCT06805305· Phase 2· Diakonos Oncology Corporation· Source

• Recruiting

  FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

  NCT06788990· Phase 2/3· Bicara Therapeutics· Source

• Recruiting

  A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

  NCT06619561· Phase 2· Deciphera Pharmaceuticals, LLC· Source

• Active, not recruiting

  A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

  NCT06561685· Phase 1· Eli Lilly and Company· Source

• Recruiting

  SMP-3124LP in Adults With Advanced Solid Tumors

  NCT06526819· Phase 1/2· Sumitomo Pharma America, Inc.· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

  NCT06313593· Phase 1· Incyte Corporation· Source

• Active, not recruiting

  N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

  NCT06061809· Phase 2· ImmunityBio, Inc.· Source

• Recruiting

  A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

  NCT06515613· Phase 1· Context Therapeutics Inc.· Source

• Recruiting

  A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

  NCT06326411· Phase 1· Nested Therapeutics, Inc· Source

• Recruiting

  A Phase 1/1b Study of IAM1363 in HER2 Cancers

  NCT06253871· Phase 1· Iambic Therapeutics, Inc· Source

• Recruiting

  Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

  NCT05145816· Phase 1/2· University of Texas Southwestern Medical Center· Source

• Active, not recruiting

  Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

  NCT05948475· Phase 3· TransThera Sciences (Nanjing), Inc.· Source

• Recruiting

  Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

  NCT05972135· Phase 2· SCRI Development Innovations, LLC· Source

• Recruiting

  Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

  NCT05636618· Phase 1/2· Perspective Therapeutics· Source

• Active, not recruiting

  Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

  NCT06088290· Phase 3· PharmaMar· Source

• Recruiting

  SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  NCT05303519· Phase 3· Nuvation Bio Inc.· Source

• Recruiting

  FOG-001 in Locally Advanced or Metastatic Solid Tumors

  NCT05919264· Phase 1/2· Parabilis Medicines, Inc.· Source

• Active, not recruiting

  Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

  NCT05539430· Phase 1· Legend Biotech USA Inc· Source

• Recruiting

  A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT05650632· Phase 1· AbbVie· Source

• Recruiting

  A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

  NCT05683418· Phase 1· Totus Medicines· Source

• Active, not recruiting

  Study of CHS-114 in Participants With Advanced Solid Tumors

  NCT05635643· Phase 1· Coherus Oncology, Inc.· Source

• Active, not recruiting

  Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

  NCT05243797· Phase 3· European Myeloma Network B.V.· Source

• Active, not recruiting

  Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

  NCT05508906· Phase 1· Olema Pharmaceuticals, Inc.· Source

• Recruiting

  Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

  NCT05523947· Phase 1/2· Yuhan Corporation· Source

• Active, not recruiting

  Improving Care After Inherited Cancer Testing

  NCT04763915· Vanderbilt-Ingram Cancer Center· Source

• Recruiting

  A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

  NCT05379595· Phase 1/2· Janssen Research & Development, LLC· Source

• Recruiting

  Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

  NCT05245500· Phase 1· Bristol-Myers Squibb· Source

• Recruiting

  Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

  NCT04903119· Phase 1· Rina Plattner· Source

• Active, not recruiting

  A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

  NCT05338775· Phase 1· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

  NCT05308654· Phase 1· AbbVie· Source

• Recruiting

  Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer

  NCT05156060· Phase 1/2· Natalie Lockney· Source

• Recruiting

  Preserving Fertility After Colorectal Cancer Study

  NCT05239338· Andreana Holowatyj, PhD, MSCI· Source

• Active, not recruiting

  A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05083169· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

  NCT04675333· Phase 2· ALX Oncology Inc.· Source

Showing 50 of 85.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Head and neck cancer8 recruiting
• Lung cancer8 recruiting
• Colorectal cancer6 recruiting
• Gastric and oesophageal cancer4 recruiting
• Liver and biliary tract cancer4 recruiting
• Pancreatic cancer4 recruiting
• Triple-negative breast cancer4 recruiting
• Bladder cancer3 recruiting
• Endometrial cancer3 recruiting
• Kidney cancer3 recruiting
• Melanoma3 recruiting
• Ovarian cancer3 recruiting
• Sarcoma3 recruiting
• Acute myeloid leukaemia2 recruiting
• Glioblastoma2 recruiting
• Metastatic breast cancer2 recruiting
• Multiple myeloma2 recruiting
• Neuroendocrine tumours2 recruiting
• Prostate cancer2 recruiting
• Amyloidosis1 recruiting
• Childhood cancers1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Meningioma1 recruiting
• Mesothelioma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting

Closed trials

• Terminated

  ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

  NCT05824559· Phase 1· MEI Pharma, Inc.· Source

• Withdrawn

  Fulvestrant + Neratinib In Breast Cancer

  NCT04901299· Phase 2· Massachusetts General Hospital· Source

• Completed

  HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

  NCT05902494· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease

  NCT05771428· Phase 2· AbbVie· Source

• Terminated

  Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

  NCT05731947· Phase 1/2· Syndax Pharmaceuticals· Source

• Completed

  A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

  NCT05753722· Phase 1· Incendia Therapeutics· Source

• Terminated

  Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

  NCT05631574· Phase 1· Biomea Fusion Inc.· Source

• Recruiting

  cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  NCT05366881· Adela, Inc· Source

• Terminated

  Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

  NCT07121829· Phase 1· Day One Biopharmaceuticals, Inc.· Source

• Terminated

  A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

  NCT05121948· Phase 1· HiberCell, Inc.· Source

• Terminated

  A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

  NCT05181540· Phase 3· Angiocrine Bioscience· Source

• Completed

  Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting

  NCT05108805· Phase 4· Vanderbilt-Ingram Cancer Center· Source

• Completed

  Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

  NCT04987203· Phase 3· AVEO Pharmaceuticals, Inc.· Source

• Terminated

  A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

  NCT04577963· Phase 1/2· Hutchmed· Source

• Recruiting

  Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

  NCT04900818· Phase 1· I-Mab Biopharma US Limited· Source

• Completed

  An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

  NCT04660812· Phase 1/2· Arcus Biosciences, Inc.· Source

• Terminated

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

  NCT04272034· Phase 1· Incyte Corporation· Source

• Completed

  A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

  NCT03776071· Phase 3· Denovo Biopharma LLC· Source

• Completed

  A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer

  NCT04322539· Phase 3· Hutchison Medipharma Limited· Source

• Terminated

  Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

  NCT04203160· Phase 1/2· University of Michigan Rogel Cancer Center· Source

• Completed

  Study of DF1001 in Patients With Advanced Solid Tumors

  NCT04143711· Phase 1/2· Dragonfly Therapeutics· Source

• Completed

  Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

  NCT04093596· Phase 1· Allogene Therapeutics· Source

• Recruiting

  A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

  NCT04064060· Phase 3· Celgene· Source

• Completed

  A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

  NCT03978689· Phase 1· Cue Biopharma· Source

• Completed

  Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies

  NCT03955783· Phase 1· Sanjay Mohan· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

  NCT03819387· Phase 1· Nitto BioPharma, Inc.· Source

• Completed

  A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD

  NCT03604692· Phase 1/2· Syndax Pharmaceuticals· Source

• Completed

  A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

  NCT03639194· Phase 1· AbbVie· Source

• Completed

  A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

  NCT03595059· Phase 1· AbbVie· Source

• Completed

  Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

  NCT03583086· Phase 1/2· Vanderbilt-Ingram Cancer Center· Source

• Completed

  CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

  NCT03425279· Phase 1/2· BioAtla, Inc.· Source

• Completed

  Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer

  NCT03263429· Phase 1/2· Vanderbilt-Ingram Cancer Center· Source

• Completed

  Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

  NCT03238196· Phase 1· Vanderbilt-Ingram Cancer Center· Source

• Completed

  Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

  NCT03238248· Phase 2· Vanderbilt-Ingram Cancer Center· Source

• Completed

  Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

  NCT02945800· Phase 2· H. Lee Moffitt Cancer Center and Research Institute· Source

• Completed

  High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

  NCT02860039· Phase 2· Vanderbilt-Ingram Cancer Center· Source

• Completed

  A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

  NCT02614066· Phase 1/2· Kite, A Gilead Company· Source

• Completed

  Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia

  NCT02658487· Phase 2· Vanderbilt-Ingram Cancer Center· Source

• Completed

  TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

  NCT02493530· Phase 1· Vanderbilt-Ingram Cancer Center· Source

• Terminated

  Connect® Myeloid Disease Registry

  NCT01688011· Celgene· Source

• Completed

  Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer

  NCT01802567· Giselle Sholler· Source

• Completed

  Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

  NCT01302834· Phase 3· Radiation Therapy Oncology Group· Source

• Completed

  S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

  NCT01120249· Phase 3· SWOG Cancer Research Network· Source

• Completed

  Biological, Genetic, and Lifestyle Risk Factors for Developing Colorectal Adenomas or Polyps in Participants Undergoing Colonoscopy

  NCT00625066· Vanderbilt University· Source

• Completed

  High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

  NCT00003641· Phase 3· ECOG-ACRIN Cancer Research Group· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Acute myeloid leukaemia21 works · 8 trials
• Myelodysplastic syndromes19 works · 6 trials